Touhouche AT, Cassagne M, Bérard E, et al. - Given that ocular adverse events (OAEs) with dupilumab were reported almost exclusively in patients treated for atopic dermatitis (AD), researchers performed a prospective, single‐centre, real‐life study to describe the incidence and nature of dupilumab induced OAEs and to evaluate the potential predisposing factors. Participants in the study were adult AD patients treated with dupilumab, who were systematically examined by an ophthalmologist before and during treatment. Forty‐six patients with a median age of 41.1 years and a median initial SCOring Atopic Dermatitis of 46.0 (IQR: 34.5‐55.5) were prospectively included. Before beginning dupilumab, AD patients with eyelid eczema or dry eye disease symptoms may be referred to an ophthalmologist to consider initiating preventive eye hydration measures. Additional multicentric and translational studies are warranted to better explain the pathophysiology of OAEs.